Invesco
AQST icon

Invesco’s Aquestive Therapeutics AQST Stock Holding History

Invesco’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Buy
89,218
+6,459
+8% +$27.2K ﹤0.01% 3365
2026
Q1 		$343K Buy
82,759
+17,766
+27% +$72.1K ﹤0.01% 3292
2025
Q4 		$420K Buy
64,993
+10,920
+20% +$68K ﹤0.01% 3267
2025
Q3 		$302K Buy
54,073
+1,260
+2% +$5.45K ﹤0.01% 3414
2025
Q2 		$175K Sell
52,813
-283
-0.5% -$812 ﹤0.01% 3548
2025
Q1 		$154K Buy
53,096
+5,152
+11% +$15.6K ﹤0.01% 3564
2024
Q4 		$171K Sell
47,944
-738,635
-94% -$3.41M ﹤0.01% 3538
2024
Q3 		$3.92M Buy
786,579
+697,538
+783% +$2.71M ﹤0.01% 2358
2024
Q2 		$232K Sell
89,041
-808,471
-90% -$2.7M ﹤0.01% 3576
2024
Q1 		$3.82M Buy
+897,512
New +$2.99M ﹤0.01% 2382
2021
Q2 		– Sell
-11,557
Closed -$60K – 3963
2021
Q1 		$60K Sell
11,557
-211,439
-95% -$1.12M ﹤0.01% 3819
2020
Q4 		$1.19M Sell
222,996
-404,448
-64% -$2.42M ﹤0.01% 2873
2020
Q3 		$3.05M Buy
+627,444
New +$4.1M ﹤0.01% 2272

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Invesco's AQST Position: Q2 2026 in Review

Invesco increased its Aquestive Therapeutics (AQST) stake by 7.8% in Q2 2026, buying an estimated $27.2K and bringing the position to 89,218 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #3365.

Invesco first reported a position in AQST in Q3 2020 and has held it in 13 quarters since. The position peaked at $3.92M in Q3 2024. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Invesco held 89,218 shares of Aquestive Therapeutics worth $371K as of Q2 2026.
  • Invesco bought 6,459 Aquestive Therapeutics shares in Q2 2026, an estimated $27.2K.
  • Aquestive Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3365 holding.
  • Invesco first reported a position in Aquestive Therapeutics in Q3 2020 and has held it in 13 quarters since.
  • Invesco's Aquestive Therapeutics position peaked at $3.92M in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.